Triple-Drug cocktail targets tough bladder cancer in early trial
NCT ID NCT06483334
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times
Summary
This study is for people with advanced bladder cancer that has spread or cannot be removed by surgery. It tests a combination of two or three drugs (MK-2870, enfortumab vedotin, and pembrolizumab) to see if they are safe and can shrink tumors. The trial has two parts: first checking safety, then checking how well the drugs work together. About 38 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center-Department of Oncology ( Site 4901)
Seoul, 05505, South Korea
-
Centre Hospitalier Lyon Sud ( Site 4606)
Pierre-Bénite, Auvergne-Rhône-Alpes, 69310, France
-
Cleveland Clinic-Taussig Cancer Center ( Site 4036)
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute ( Site 4047)
Boston, Massachusetts, 02115, United States
-
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 4405)
Milan, 20133, Italy
-
Hospital Clinico San Carlos ( Site 4765)
Madrid, 28040, Spain
-
Hospital Universitari Vall d'Hebron-Oncology ( Site 4767)
Barcelona, 08035, Spain
-
Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 4041)
Salt Lake City, Utah, 84112, United States
-
Icahn School of Medicine at Mount Sinai ( Site 4018)
New York, New York, 10029, United States
-
Indiana University Melvin and Bren Simon Cancer Center ( Site 4011)
Indianapolis, Indiana, 46202, United States
-
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 4406)
Naples, 80131, Italy
-
National Cheng Kung University Hospital-Clinical Trial Center ( Site 4803)
Tainan, 704, Taiwan
-
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 4302)
Amsterdam, North Holland, 1066 CX, Netherlands
-
Ospedale San Raffaele-Oncologia Medica ( Site 4403)
Milan, Lombardy, 20132, Italy
-
Princess Margaret Cancer Centre ( Site 4106)
Toronto, Ontario, M5G 2M9, Canada
-
Rabin Medical Center-Oncology ( Site 4504)
Petah Tikva, 4941492, Israel
-
Rambam Health Care Campus ( Site 4501)
Haifa, 3109601, Israel
-
Samsung Medical Center ( Site 4902)
Seoul, 06351, South Korea
-
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 4903)
Seoul, 03722, South Korea
-
Sheba Medical Center-ONCOLOGY ( Site 4503)
Ramat Gan, 5265601, Israel
-
Siteman Cancer Center ( Site 4038)
St Louis, Missouri, 63108, United States
-
St Bartholomew s Hospital ( Site 4206)
London, London, City of, EC1A 7BE, United Kingdom
-
The Ottawa Hospital - General Campus ( Site 4105)
Ottawa, Ontario, K1H 8L6, Canada
-
University of California San Francisco HDFCCC ( Site 4044)
San Francisco, California, 94158, United States
-
University of Chicago Medical Center ( Site 4037)
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.